- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S4933
| Related Targets | Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR |
|---|---|
| Other Dopamine Receptor Products | MPTP Hydrochloride Trifluoperazine Trifluoperazine 2HCl Penfluridol SCH-23390 hydrochloride Domperidone SKF38393 HCl Sulpiride Azaperone C-DIM12 |
|
In vitro |
Water : <1 mg/mL Ethanol : <1 mg/mL 5%TFA : 33mg/ml mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 73.89 | Formula | CLi2O3 |
Storage (From the date of receipt) | 3 years-21°C powder |
|---|---|---|---|---|---|
| CAS No. | 554-13-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Li2CO3 | Smiles | [Li+].[Li+].C(=O)([O-])[O-] | ||
| References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06396312 | Recruiting | Depressive; Disorder Major Single Episode Major With Psychotic Symptoms|Depressive; Disorder Major Single Episode Major (Without Psychotic Symptoms)|Depressive Disorder Major Recurrent With Psychotic Symptoms|Depressive Disorder Major Recurrent Without Psychotic Symptoms|Depressive Disorder Treatment-Resistant Class I or II|Depressive Disorder Major Moderate|Depressive Disorder Major Severe |
Max-Planck-Institute of Psychiatry |
April 2 2024 | -- |
| NCT06134349 | Recruiting | Bipolar Disorder |
Leiden University Medical Center |
March 13 2024 | -- |
| NCT05982340 | Recruiting | Acute Kidney Injury Due to Sepsis|Proximal Tubule Function|Lithium Clearance |
University Hospital of North Norway |
August 1 2023 | -- |
| NCT05044611 | Recruiting | Bipolar Disorder |
Assistance Publique - Hôpitaux de Paris |
January 11 2023 | Phase 4 |
| NCT05648435 | Completed | Acute Kidney Injury |
University Hospital of North Norway |
December 7 2022 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.